Johnson & Johnson Showcases Neuropsychiatry Innovations at Psych Congress
At the annual U.S. Psychiatric and Mental Health Congress (Psych Congress), Johnson & Johnson (J&J) is set to present 23 abstracts featuring new real-world and clinical trial data from its neuropsychiatry portfolio and pipeline. Key highlights include new five-year data reinforcing the long-term safety and efficacy of SPRAVATO® (esketamine) in patients with treatment-resistant depression (TRD), and insights into the clinical, humanistic, and economic burden of anhedonia in adults with major depressive disorder (MDD).
SPRAVATO®, a CIII nasal spray, is approved by the U.S. Food and Drug Administration for use in combination with an oral antidepressant for adults with TRD and depressive symptoms in adults with MDD with acute suicidal ideation or behavior. The presentations also include a large real-world analysis highlighting the link between reducing relapse and improving survival in schizophrenia.
J&J's commitment to neuroscience innovation is evident in its robust portfolio and pipeline, aimed at addressing the significant unmet needs of patients with serious mental illnesses. The company's presentations at Psych Congress underscore its dedication to advancing research and understanding of MDD and schizophrenia, with the goal of delivering transformational therapies.
Key presentations include:
- New five-year, real-world safety data from nearly 35,000 adults treated with SPRAVATO®.
- Novel insights into the burden of anhedonia in adults with MDD.
- Results from an analysis of more than 30,000 adults with schizophrenia, emphasizing the link between symptom relapse and risk of death.
J&J's neuropsychiatry portfolio also includes long-acting injectables (LAIs) for schizophrenia, such as INVEGA SUSTENNA®, INVEGA TRINZA®, and INVEGA HAFYERA®, which offer varied dosing options and are recognized for their role in controlling symptoms and reducing costly relapses.
The Psych Congress serves as a platform for J&J to share its latest research findings and reinforce its position as a leader in neuroscience, committed to improving the lives of those affected by challenging-to-treat mental illnesses.